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Abstract
OBJECTIVES: Surgical aortic valve replacement (SAVR) for the treatment of in very old patients with severe aortic stenosis is associated
with a high risk of morbidity and mortality. Transcatheter aortic valve implantation (TAVI) has become the preferred alternative. Therefore,
we sought to evaluate outcomes in very old patients who underwent SAVR versus TAVI.
METHODS: A total of 169 consecutive patients aged >_85 years underwent TAVI (n = 68) or SAVR (n = 101). A propensity score adjustment
was used to compare outcomes including cost analysis.
RESULTS: The propensity score generated 40 pairs of patients with similar baseline characteristics. The TAVI group experienced atrioven-
tricular block (37.5% vs 5%, P < 0.01) more frequently, a longer stay in the intensive care unit (median 5 days, range 1–35 vs median 2 days,
range 1–6, P < 0.01) but a lower rate of new-onset atrial fibrillation (15% vs 47.5%, P < 0.01). The 30-day mortality rate was similar in the un-
matched and matched cohorts (8.8% vs 5.0%, P = 0.32; 10% vs 7.5%, P = 0.69). One, 3- and 5-year overall survival rates (80% vs 90%, 56% vs
79%, 37% vs 71%, P < 0.01) and freedom from major adverse cardiac and cardiovascular events (72% vs 90%, 46% vs 76%, 17% vs 68%,
P < 0.01) were lower in the TAVI group. An overall cost analysis indicated that TAVI was more expensive (e2084 vs e19 891).
CONCLUSIONS: In patients 85 years and older, SAVR seems to offer good short- and mid-term clinical outcomes compared to TAVI.
Advanced age alone would not be an indication for TAVI in old–old patients.
Keywords: Over 85 • Aortic valve replacement • TAVI • Elderly • Aortic stenosis
BACKGROUND
Aortic stenosis is the most common valvular disease in the eld-
erly [1, 2]. It is a frequent cause of morbidity and mortality [3],
with a 2-year 90% mortality rate in symptomatic patients without
surgery [4, 5]. Notably, improving surgical techniques and post-
operative care resulted in a low-operative mortality rate after sur-
gical aortic valve replacement (SAVR) and improved survival
rates in the elderly population [1–6]. However, referring phys-
icians still have the perception of a poor outcome after SAVR [3];
consequently, there is an increased likelihood of elderly patients
being managed conservatively. In fact, although older age is not
a contraindication for SAVR [6, 7], it is a common clinical practice
to recommend TAVI for old–old patients even though the
preoperative risk is not prohibitive or particularly high [7, 8].
Hence, we evaluated outcomes in old–old patients who under-
went SAVR versus TAVI.
METHODS
Patient population
Between 2007 and 2015, 169 consecutive patients >_85 years with
severe symptomatic aortic stenosis underwent SAVR or TAVI at
the University Hospital of Udine, Italy. Patient selection and de-
termination of further indications for TAVI or SAVR were per-
formed by the heart team: cardiac surgeon, clinical cardiologist,
interventional cardiologist, radiologist and anaesthesiologist.
During the study period, there was a progressive shift to TAVI for
patients who were considered inoperable to patients considered
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at high risk based on a logistic EuroSCORE [9] or the presence of
porcelain aorta or frailty.
Procedures
For SAVR, stented and stentless biological prostheses were im-
planted using a full sternotomy and cardiopulmonary bypass. In
patients with severe coronary artery disease, coronary artery
bypass graft was performed concomitantly. For TAVI, the
balloon-expandable Edwards SAPIEN-XT or SAPIEN-3 (Edwards
Lifesciences, Irvine, CA, USA) or self-expandable CoreValve
(Medtronic, Inc., Minneapolis, MN, USA) bioprostheses were im-
planted. The type of TAVI access, transfemoral, transaortic or
transapical, was selected based on assessment using a pre-TAVI
multi-imaging model. Whenever possible, the transfemoral ap-
proach was considered the first option. In patients with severe
coronary artery disease affecting major vessels, the patients were
treated with angioplasty 2–4 weeks before the TAVI procedure.
Outcomes
Early and late outcomes of SAVR and TAVI patients were com-
pared using several perioperative end points according to the
Valve Academic Research Consortium-2 guidelines [10]. Overall
survival was defined as freedom from all-cause mortality. A major
adverse cardiovascular and cerebral event (MACCE) was defined
as a compound of all-cause mortality, myocardial infarction,
major stroke (modified Rankin score >_2) and valve-related
rehospitalization.
Economic analysis was performed according to the regional
cost reported by the health department grossly as follows: TAVI
prosthesis, e20 000; surgical bioprostheses, e2500; catheterisation
laboratory equipment expenses including equipment and doc-
tors and nurses, e2520; operating room expenses including car-
diopulmonary bypass, doctors and nurses e1966; reoperation for
bleeding, e291; coronary angiography, e750; angioplasty with
stent implantation, e1665; pacemaker implantation, e2991; intra-
aortic balloon pump insertion, e1640; haemodialysis, e230;
blood transfusions, e136; intensive care unit stay, e1400 per day;
intermediate care stay, e1000 per day; ward stay, e650 per day;
computed tomography scans, e120; echocardiogram, e70.
STATISTICAL ANALYSIS
Continuous variables were expressed as mean ± standard devi-
ation or median and range, according to the data distribution.
The data were analysed using the Shapiro–Wilk test to verify the
normal distribution. Categorical variables were presented as ab-
solute numbers and percentages.
The Student t-test or the Mann–Whitney U test was used to
compare continuous variables between groups, as appropriate.
Comparison of categorical variables was performed by v2 analysis
or the Fisher exact test, as appropriate.
Due to imbalances in baseline characteristics between the
TAVI and SAVR cohorts, a propensity score analysis was per-
formed. Propensity scores were generated from a multivariable
logistic regression model in which TAVI/SAVR status regressed on
the baseline variables [age, New York Heart Association (NYHA)
class, atrial fibrillation, logistic EuroSCORE, preoperative myocar-
dial infarction, mitral regurgitation > moderate, frailty, previous
angioplasty and cardiac surgery]. The matching method used to
generate balanced cohorts was the single nearest neighbour,
without replacement. [11].
Overall survival was defined as freedom from all-cause mortal-
ity. MACCE was defined as a compound of all-cause mortality,
myocardial infarction, major stroke (modified Rankin score >_2)
and valve-related rehospitalization.
Overall survival and MACCE-free survival were determined
using the Kaplan–Meier approach for unmatched and matched
TAVI and SAVR cohorts. Comparisons between survival distribu-
tions were performed using the log-rank test, with estimation of
the hazard ratio (HR) from a Cox regression model, after the pro-
portional hazards assumption had been verified. Univariate and
multivariate Cox regression analyses were also performed to de-
termine the prognostic implications of each variable on overall
survival and MACCE. Multivariate stepwise analyses included all
variables significant at P <_ 0.10 in univariate analysis. Retention in
the stepwise model required that the variable be significant at
P < 0.05 in a multivariate analysis. Results are presented as HRs
and 95% confidence intervals.
Analyses were performed with the Stata/SE 14.1 program for
the Mac computer.
RESULTS
The baseline clinical and echocardiographic characteristics of the
study populations are presented in Table 1. TAVI patients were
older (median age 87.8 years, range 85–94 years vs median age
85.9 years, range 85–89.6 years; P < 0.01) and more symptomatic in
terms of NYHA functional class (median NYHA class 3, range 2–4
vs median NYHA class 2, range 1–4, P < 0.01). They also presented
more frequently with atrial fibrillation (52.9% vs 29.7%, P <0.01),
previous angioplasty (29.9% vs 4.0%, P < 0.01) or a cardiac surgical
procedure (16.2% vs 1% P < 0.01), frailty (7.4% vs 0%, P < 0.01), por-
celain aorta (13.2% vs 0%, P < 0.01), mitral regurgitation > moderate
(10.3% vs 2% P = 0.02), a higher logistic EuroSCORE (median logis-
tic EuroSCORE 22%, range 5–63% vs median logistic EuroSCORE
15.5%, range 5.1–62.8%, P < 0.01) and a higher EuroSCORE II (me-
dian EuroSCORE II 3.4%, range 1.1–22.6% vs median EuroSCORE II
2.6%, range 1.2–20.5%, P < 0.01).
Procedures
In the TAVI group, there were 51 (75%) transfemoral procedures,
15 (22%) transapical procedures and 2 (3%) transaortic proced-
ures. The balloon-expandable SAPIEN-XT or SAPIEN-3 biopros-
thesis was used in 29 patients (43%), and the self-expanding
CoreValve was used in 39 (57%) patients. The median implanted
size was 26 (21–31) mm. Ten patients (15%) underwent further
postimplantation dilatation because of residual aortic regurgita-
tion. TAVI was performed following coronary angioplasty in 20
cases (29%), and 13 patients (19%) received an incomplete
revascularization.
In the SAVR group, different bioprostheses were used: Magna
(Edwards Lifesciences, Irvine, CA, USA) in 37 cases, Mitroflow
(Livanova, London, UK) in 11, Hancock II (Medtronic,
Minneapolis, MA, USA ) in 11, Solo (Livanova, London, UK) in 11,
others in 41. The median implanted size was 23 (19–27) mm.
Seventy-two patients (71%) underwent combined procedures,
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(60 patients). Other surgical procedures included radiofrequency
ablation (4 patients), septal myectomy (3 patients), mitral valve
repair (2 patients) and others (3 patients).
Outcomes
The postoperative clinical and echocardiographic characteristics
of the study populations are presented in Table 2. The TAVI
group showed more atrioventricular blocks (33.8% vs 3.0%,
P < 0.01), major vascular complications (7.4% vs 0%, P < 0.01) and
longer stays in the intensive care unit (median stay 4 days, range
0–35 vs median stay 2 days, range 1–60, P < 0.01); the TAVI group
had a lower rate of acute kidney injury (7.4% vs 21.8%, P = 0.01)
and new-onset atrial fibrillation (14.7% vs 47.5%, P < 0.01)
compared with SAVR group. Importantly, the 30-day mortality
rate was similar in both groups (8.8% vs 5.0%, P = 0.32).
Echocardiography at hospital discharge showed similar peak
and mean gradients (16.6 ± 7 mmHg vs 17.9 ± 6.5, P = 0.35;
9.8 ± 4.9 mmHg vs 9.3 ± 3.9 mmHg, P = 0.59, respectively) but
TAVI patients showed higher rates of paravalvular leak >_ moder-
ate (10.5% vs 0%, P < 0.01).
The median follow-up period was 28 months (range 0.1–84) in
the TAVI group and 47 months (range 0.1–108) in SAVR group.
The estimated 1-, 3- and 5-year overall survival rates were
81%, 61% and 40% in the TAVI group and 91%, 79% and 71% in
the SAVR group, P < 0.01 (Fig. 1). The estimated 1, 3- and 5-year
MACCE-free survival rates were 63%, 41% and 21% in TAVI group
and 88%, 75% and 67% in the SAVR group, respectively, P < 0.01
(Fig. 2).
Multivariate Cox regression analysis showed that risk factors
for mortality were mitral regurgitation >moderate (HR 3.571,
1.598–7.977, P < 0.01) and renal failure (HR 2.045, 1.199–3.489,
P = 0.01), whereas systemic hypertension was a protective factor
(HR 0.529, 0.316–0.888, P = 0.02). Prognostic variables that have
been shown to be risk factors for MACCE in the multivariate Cox
proportional hazards model were TAVI group (HR 2.917, 1.802–
4.721, P < 0.01), mitral regurgitation > moderate (HR 3.156, 1.435–
6.941, P < 0.01) and renal failure (HR 2.088, 1.281–3.403, P < 0.01),
whereas systemic hypertension was a protective factor (HR 0.604,
0.375–0.976, P = 0.04).
Propensity score analysis
The propensity score matching process resulted in 40 pairs of pa-
tients with similar baseline characteristics. Baseline characteristics
of the matched populations are summarized in Table 1. The early
outcomes of the matched population according to the type of
treatment are reported in Table 2. In the TAVI group, there were
more atrioventricular blocks (37.5% vs 5%, P < 0.01), longer time
in the intensive care unit (median 5 days, range 1–35 vs median
2 days, range 1–6, P < 0.01) but a lower rate of new-onset atrial
fibrillation (15% vs 47.5%, P < 0.01). Postoperative echocardio-
graphic findings (Table 2) were similar in the 2 groups but indi-
cated a higher rate of mild (46.2% vs 3.9%, P < 0.01)
and >_ moderate paravalvular leak (10.3% vs 0%, P = 0.04) among
TAVI patients.
The 30-day mortality rate was similar in the 2 groups (10% vs
7.5%, P = 0.69). The estimated 1, 3- and 5-year overall survival
Table 1: Baseline clinical and echocardiographic data
Full cohort (n = 169) Propensity score matched cohort (n = 80)
TAVI (n = 68) SAVR (n = 101) P-value TAVI (n = 40) SAVR (n = 40) P-value
Clinical variables
Age (years, median, range) 87.8 (85–94) 85.9 (85–89.6) <0.01 87.6 (85–92.6) 86.7 (85–91.6) 0.08
Female sex 36 (52.9%) 54 (53.5%) 0.95 22 (55%) 27 (67.5%) 0.25
NYHA (median, range) 3 (2–4) 2 (1–4) <0.01 3 (2–4) 3 (1–4) 0.40
Diabetes 16 (23.5%) 17 (16.8%) 0.28 6 (15%) 6 (15%) 1.00
COPD 14 (20.6%) 16 (15.8%) 0.43 12 (30%) 9 (22.5%) 0.45
Renal failure (GFR <30) 18 (26.5%) 20 (20.0%) 0.33 7 (17.5%) 8 (20.5%) 0.73
Hypertension 52 (76.5%) 81 (80.2%) 0.56 28 (70%) 32 (80%) 0.30
Peripheral vascular disease 18 (26.5%) 25 (24.8%) 0.80 9 (22.5%) 8 (20%) 0.79
Cerebrovascular disease 7 (10.3%) 5 (5%) 0.19 2 (5%) 0 (0%) 0.15
Atrial fibrillation 36 (52.9%) 30 (29.7%) <0.01 19 (47.5%) 17 (42.5%) 0.65
Previous myocardial infarction 16 (23.5%) 10 (9.9%) 0.02 7 (17.5%) 8 (20%) 0.78
Previous PTCA 20 (29.9%) 4 (4.0%) <0.01 7 (17.5%) 3 (7.5%) 0.18
Previous cardiac surgery 11 (16.2%) 1 (1%) <0.01 5 (12.5%) 1 (2.5%) 0.09
Coronary artery disease 36 (52.9%) 61 (60.4%) 0.34 15 (37.5%) 23 (57.5%) 0.07
Frailty 5 (7.4%) 0 (0%) <0.01 0 (0%) 0 (0%) 1.00
Porcelain aorta 9 (13.2%) 0 (0%) <0.01 0 (0%) 0 (0%) 1.00
Logistic EuroSCORE (median, range) 22 (5–63) 15.5 (5.1–62.8) <0.01 21.6 (5–63) 18.7 (5.1–62.8) 0.11
EuroSCORE II (median, range) 3.4 (1.1–22.6) 2.6 (1.2–20.5) <0.01 3.2 (1.1–14.8) 3.2 (1.4–22.6) 0.67
Echocardiographic data
LVEF (%) 56.9 (12.1%) 59.2 (11.7) 0.22 57 ± 12.3 58.5 ± 13 0.58
Aortic valve area (cm2, mean ± SD) 0.65 ± 0.48 0.72 ± 0.21 0.29 0.58 ± 0.5 0.7 ± 0.2 0.20
Mean gradient (mmHg, mean ± SD) 42.7 ± 14.8 45.9 ± 17.2 0.26 43.8 ± 16 46.4 ± 18.8 0.55
Mitral regurgitation >moderate 7 (10.3%) 2 (2%) 0.02 3 (7.5%) 1 (2.5%) 0.31
Pulmonary hypertension 22 (32.4%) 24 (23.8%) 0.22 11 (27.5%) 12 (30%) 0.81
TAVI: transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement; NYHA: New York Heart Association; COPD: chronic obstructive pul-
monary disease; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; PTCA: percutaneous transluminal coronary angioplasty; SD: standard
deviation.
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rates in the matched groups were 80%, 56% and 37% in the TAVI
group and 90%, 79% and 71% in the SAVR group (Fig. 3). In the
TAVI group, the causes of death during the follow-up period
were cardiac in 7 patients (41%), infective in 7 (41%), neoplastic
in 1 (6%) and other in 2 (12%). In the SAVR group, 2 patients
(20%) died of cardiac causes, 1 (10%) of infection, 2 (20%) of neo-
plasms and 5 (50%) of other causes. The estimated 1, 3- and
5-year MACCE-free survival rates were 72%, 46% and 17% in the
TAVI group and 90%, 76% and 68% in the SAVR group, respect-
ively (Fig. 4). There was a statistically significant difference in
terms of overall survival and freedom from MACCE between the
TAVI and SAVR groups (both P < 0.01). After multivariate Cox
proportional hazards model analysis, the TAVI approach had the
only independent predictive factor for mortality (HR 2.510,
1.238–5.089, P = 0.01), whereas the TAVI approach (HR 3.073,
1.539–6.135, P < 0.01) and chronic obstructive pulmonary disease
(HR 2.576, 1.295–5.124, P < 0.01) were independent predictors
for MACCE (Tables 3 and 4).
Table 2: Perioperative outcomes
Full cohort (n = 169) Propensity score matched cohort (n = 80)
Variables TAVI (n = 68) SAVR (n = 101) P-value TAVI (n = 40) SAVR (n = 40) P-value
Acute kidney injury 5 (7.4%) 22 (21.8) 0.01 4 (10%) 7 (17.5%) 0.33
Bleeding 2 (2.9%) 3 (3.0%) 0.99 1 (2.5%) 2 (5%) 0.56
Stroke 0 (0%) 0 (0%) 1.00 0 (0%) 0 (0%) 1.00
Wound infection 2 (2.9%) 1 (1%) 0.30 1 (2.5%) 1 (2.5%) 1.00
Atrioventricular block 23 (33.8%) 3 (3.0%) < 0.01 15 (37.5%) 2 (5%) <0.01
Atrial fibrillation 10 (14.7%) 48 (47.5%) < 0.01 6 (15%) 19 (47.5%) <0.01
Major vascular complications 5 (7.4%) 0 (0%) <0.01 3 (7.5%) 0 (0%) 0.08
LVEF (%, mean ± SD) 58 ± 11 63.6 ± 10 <0.01 59.9 ± 11.3 63.3 ± 9.4 0.19
Peak gradient (mmHg, mean ± SD) 16.6 ± 7 17.9 ± 6.5 0.35 15.9 ± 5.8 17.3 ± 6.2 0.46
Mean gradient (mmHg, mean ± SD) 9.8 ± 4.9 9.3 ± 3.9 0.59 10.4 ± 4.9 9.3 ± 3.8 0.39
Paravalvular leak >2 7 (10.5%) 0 (0%) <0.01 4 (10.3%) 0 (0%) 0.04
ICU stay (days, median, range) 4 (0–35) 2 (1–60) < 0.01 5 (1–35) 2 (1–6) <0.01
Hospital stay (days, median, range) 12 (3–95) 12 (7–19) 0.71 12 (5–9) 14.5 (7–19) 0.95
30-Day mortality rate 6 (8.8%) 5 (5.0%) 0.32 4 (10%) 3 (7.5%) 0.69
TAVI: transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement; LVEF: left ventricular ejection fraction; ICU: intensive care unit.
Figure 1: Overall actuarial survival. Figure 3: Overall survival after propensity matching.
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Cost analysis
The mean cost in the TAVI group was much higher than that in
the SAVR group (e42 084 vs e19 891). This significant difference
might be explained by a more complex preoperative patient
screening (for coronary angiography, CT scan, prolonged hospi-
talization, e2140 vs e820), longer hospital stay in the inter-
mediate care unit (e16 390 vs e13 950) and higher rate of
postoperative complications including pacemaker implantation
(e1034 vs e155) in addition to the higher cost of the TAVI pros-
thesis itself.
DISCUSSION
The main message of this study is that patients with severe aortic
stenosis aged >_85 years can be effectively treated with SAVR or
TAVI, obtaining satisfactory rates of morbidity and mortality with
either approach. TAVI seems to have worse mid-term outcomes
in terms of survival and freedom from MACCE even after pro-
pensity matching, and its costs appear to be double those with
SAVR.
Clinical outcomes
In old–old patients, a higher surgical risk is generally accepted
because of multiple comorbid conditions. Vasques et al. [1] per-
formed a meta-analysis of 13 216 contemporary octogenarian
patients that showed a postoperative mortality rate of 6.7% for
SAVR, and a previous nonagenarians series reported a short-
term mortality rate of 11.1–17.1%, showing an increased risk
in cases of concomitant myocardial revascularization [12, 13].
Transcatheter aortic valve implantation in a series of old–old pa-
tients showed a 30-day mortality rate between 3.2% and 6.9%
[14, 15]. Our 30-day mortality rate in the SAVR group was 5%
(7.5% after matching), whereas in the TAVI group, it was 8.8%
(10% after matching), which could be partially explained by the
learning curve because we included all patients who were over
85 years old by the beginning of the TAVI program. Recently, a
comparison between SAVR and TAVI showed similar 30-day
mortality rates (6% vs 7.9%, P = 0.35) in nonagenarians [16], but
few studies so far have analysed the long-term survival rates of
old–old patients undergoing TAVI and SAVR. Even after propen-
sity matching, our results showed a better survival rate and
Figure 4: Major adverse cardiovascular and cerebral event-free survival after
propensity matching.
Table 3: Risk factors in score matched cohort for long-term mortality and major adverse cardiac and cardiovascular events at uni-
variate Cox regression
Overall survival MACCE
HR 95% CI P-value HR 95% CI P-value
TAVI group 2.510 1.238–5.089 0.01 3.436 1.749–6.750 <0.01
Age 1.021 0.824–1.265 0.85 1.074 0.889–1.299 0.46
Female sex 0.925 0.468–1.829 0.82 1.179 0.636–2.188 0.60
NYHA 1.095 0.597–2.010 0.77 1.191 0.679–2.089 0.54
Diabetes 0.833 0.323–2.147 0.71 0.699 0.274–1.783 0.45
COPD 1.948 0.954–3.976 0.07 2.528 1.305–4.898 <0.01
Renal failure 1.240 0.541–2.842 0.61 1.171 0.541–2.539 0.69
Hypertension 0.479 0.242–0.950 0.04 0.493 0.261–0.931 0.03
Peripheral vascular disease 0.418 0.148–1.183 0.10 1.061 0.507–2.222 0.88
Atrial fibrillation 1.409 0.730–2.721 0.31 1.311 0.711–2.451 0.39
Logistic EuroSCORE 1.001 0.979–1.024 0.92 1.008 0.988–1.028 0.43
EuroSCORE II 0.963 0.881–1.052 0.40 0.980 0.910–1.055 0.58
Left ventricular ejection fraction 0.997 0.970–1.026 0.86 0.988 0.963–1.013 0.35
Mean gradient 0.991 0.968–1.016 0.50 0.992 0.971–1.014 0.47
Previous myocardial infarction 0.691 0.287–1.666 0.41 0.707 0.313–1.596 0.40
Previous PTCA 0.693 0.212–2.269 0.55 1.260 0.492–3.227 0.63
Previous cardiac surgery 0.655 0.157–2.730 0.56 0.806 0.248–2.612 0.72
Coronary disease 1.020 0.530–1.963 0.95 1.025 0.559–1.880 0.94
Mitral regurgitation > moderate 3.361 1.170–9.654 0.02 4.788 1.612–14.22 <0.01
Paravalvular leak >2 1.033 0.247–4.318 0.96 1.622 0.499–5.270 0.42
MACCE: major adverse cardiac and cardiovascular events; TAVI: transcatheter aortic valve implantation; NYHA: New York Heart Association; COPD: chronic
obstructive pulmonary disease; PTCA: percutaneous transluminal coronary angioplasty; HR: hazard ratio; CI: confidence interval.
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freedom from MACCE in SAVR group. The OBSERVANT study
showed no difference in mortality rate and freedom from
MACCE at 1 and 3 years in octogenarians [17], whereas the US
Pivotal Trial showed a superiority in terms of death from any
cause at 1 year in the TAVI group (14.2% vs 19.1%); similar results
seem to be confirmed at 3 years [8].
Given the low levels of early deaths and the satisfactory long-
term survival rates obtained with SAVR, as well as the excellent
quality of life [4, 18], exclusion from surgical intervention based
solely on age may hamper patients from receiving the best stand-
ard of care. In clinical practice, older patients are more frequently
referred for TAVI instead of SAVR because of a perceived lower
risk of intervention and shorter recovery time. But determination
of surgical risk should not depend on patient age alone; rather, the
presence of significant comorbidities, such as renal failure, stroke,
urgent status and frailty [7] should also be considered. Moreover,
old patients are more frequently affected by additional heart dis-
eases such as diffuse coronary disease and mitral regurgitation [19]
that can also be treated surgically. In fact, in the SAVR group,
moderate or severe mitral regurgitation was treated concomi-
tantly, and coronary artery bypass graft permitted complete revas-
cularization. In the TAVI group, occluded coronary vessels could
not be stented, and percutaneous transluminal coronary angio-
plasty was performed only in major coronary arteries. The incom-
plete revascularization and the untreated mitral regurgitation
could have influenced the high rate of hospital readmissions for
heart failure as well as deaths of cardiac reasons. Therefore, even
in old patients, whenever possible, completeness should be pre-
ferred to the less invasiveness of TAVI.
Complications and postoperative morbidity can have a signifi-
cant effect on survival and quality of life of extremely elderly
patients [18, 20–22]. Our experience confirms the different distri-
bution of complications with TAVI and SAVR shown in previous
studies: The need for permanent pacemaker implantation, the inci-
dence of moderate or severe paravalvular regurgitation and major
vascular complications are higher in the TAVI patient population.
Conversely, patients treated with TAVI are at significantly lower
risk for periprocedural bleeding and acute kidney injury [18, 20].
Cost-effectiveness
The increased costs of highly technical cardiovascular treatments
and the progressively insufficient economic resources force
health care organizations to optimize cost-effectiveness in health
care strategies. Therefore, econometric analysis plays an import-
ant role in the evaluation of any novel cardiovascular therapy.
In accordance with a systematic review of the literature, TAVI
seems to be more expensive and less effective for high-risk pa-
tients, with a mean total cost of US$81 638 and US$43 974 for
TAVI and SAVR, respectively (P < 0.01) [23]. In our experience, the
costs associated with TAVI were double those associated with
SAVR, mainly due to the high cost of the prosthesis and the
higher demand for preoperative investigations. On the other
hand, such increased costs are not balanced by a lower rate of
postoperative complications and thus a shorter hospital stay, as
expected. In fact, TAVI patients needed a longer stay in inter-
mediate care and a high rate of pacemaker implantation (that led
to even longer hospital stays). In both groups, hospitalization was
longer than that described in the literature because of the lack of
rehabilitation centres in our region to which we could rapidly
transfer the patients.
Limitations
The present study has several limitations. The retrospective and
observational natures of the study are certainly associated with
selection bias. Nonagenarians are less likely to comply with a
structured follow-up program. Therefore, echocardiographic
findings and mid-term data were available only for those patients
requiring hospital readmission, so the needed data were not col-
lected. The limited number of matched patients did not permit
us to make definitive conclusions. Larger studies are necessary.
CONCLUSIONS
In patients 85 years and older, SAVR offers satisfactory short- and
mid-term clinical outcomes compared to TAVI. Our results sug-
gest that in this subset of old–old patients, advanced age alone
would not be an indication for TAVI. An individual, patient-
centred strategy should be paramount in the decision-making
process.
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